Granules India Limited (GRANULES.BO)
INR 444.65
(1.8%)
INR 444.65
(1.8%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.81 Billion INR | -13.37% |
| 2022 | 7.48 Billion INR | 28.05% |
| 2021 | 5.84 Billion INR | -18.76% |
| 2020 | 7.19 Billion INR | 66.92% |
| 2019 | 4.31 Billion INR | 54.0% |
| 2018 | 2.79 Billion INR | 37.1% |
| 2017 | 2.04 Billion INR | -13.4% |
| 2016 | 2.35 Billion INR | 7.64% |
| 2015 | 2.19 Billion INR | 40.03% |
| 2014 | 1.56 Billion INR | 24.18% |
| 2013 | 1.25 Billion INR | 110.61% |
| 2012 | 598.21 Million INR | 5.26% |
| 2011 | 568.29 Million INR | 44.45% |
| 2010 | 393.42 Million INR | -28.66% |
| 2009 | 551.45 Million INR | 0.0% |
| 2008 | - INR | -100.0% |
| 2007 | 256.31 Million INR | 10.83% |
| 2006 | 231.25 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 2.06 Billion INR | 1.91% |
| 2023 Q4 | 2.02 Billion INR | 2.24% |
| 2023 Q3 | 1.98 Billion INR | 23.46% |
| 2023 FY | 6.48 Billion INR | -13.37% |
| 2023 Q1 | 875.82 Million INR | -51.18% |
| 2023 Q2 | 1.6 Billion INR | 83.2% |
| 2022 Q4 | 1.79 Billion INR | -1.92% |
| 2022 Q3 | 1.82 Billion INR | -8.0% |
| 2022 FY | 7.48 Billion INR | 28.05% |
| 2022 Q1 | 1.68 Billion INR | 10.24% |
| 2022 Q2 | 1.98 Billion INR | 18.26% |
| 2021 Q4 | 1.52 Billion INR | 13.39% |
| 2021 Q1 | 1.62 Billion INR | 5.13% |
| 2021 FY | 5.84 Billion INR | -18.76% |
| 2021 Q3 | 1.34 Billion INR | 20.81% |
| 2021 Q2 | 1.11 Billion INR | -31.29% |
| 2020 Q1 | 1.55 Billion INR | 35.62% |
| 2020 Q2 | 2.23 Billion INR | 44.11% |
| 2020 Q4 | 1.54 Billion INR | -19.35% |
| 2020 FY | 7.19 Billion INR | 66.92% |
| 2020 Q3 | 1.91 Billion INR | -14.51% |
| 2019 Q4 | 1.14 Billion INR | -10.39% |
| 2019 Q1 | 1.17 Billion INR | 36.74% |
| 2019 Q3 | 1.27 Billion INR | 4.68% |
| 2019 Q2 | 1.21 Billion INR | 3.97% |
| 2019 FY | 4.31 Billion INR | 54.0% |
| 2018 Q3 | 942.54 Million INR | 3.34% |
| 2018 FY | 2.79 Billion INR | 37.1% |
| 2018 Q1 | 774.45 Million INR | 135.42% |
| 2018 Q2 | 912.12 Million INR | 17.78% |
| 2018 Q4 | 857.77 Million INR | -8.99% |
| 2017 Q1 | 627.45 Million INR | 3.65% |
| 2017 FY | 2.04 Billion INR | -13.4% |
| 2017 Q4 | 328.96 Million INR | -45.31% |
| 2017 Q3 | 601.5 Million INR | -14.08% |
| 2017 Q2 | 700.09 Million INR | 11.58% |
| 2016 FY | 2.35 Billion INR | 7.64% |
| 2016 Q4 | 605.37 Million INR | -2.21% |
| 2016 Q3 | 619.03 Million INR | 3.83% |
| 2016 Q2 | 596.17 Million INR | 8.02% |
| 2016 Q1 | 551.92 Million INR | -15.15% |
| 2015 FY | 2.19 Billion INR | 40.03% |
| 2015 Q4 | 650.44 Million INR | 24.83% |
| 2015 Q2 | 550.4 Million INR | 9.87% |
| 2015 Q1 | 500.96 Million INR | 51.86% |
| 2015 Q3 | 521.05 Million INR | -5.33% |
| 2014 Q4 | 329.89 Million INR | -20.95% |
| 2014 Q3 | 417.33 Million INR | 4.82% |
| 2014 Q2 | 398.14 Million INR | -4.19% |
| 2014 FY | 1.56 Billion INR | 24.18% |
| 2014 Q1 | 415.55 Million INR | 21.48% |
| 2013 Q3 | 381.3 Million INR | 37.33% |
| 2013 Q4 | 342.07 Million INR | -10.29% |
| 2013 Q2 | 277.66 Million INR | 7.26% |
| 2013 Q1 | 258.88 Million INR | 47.76% |
| 2013 FY | 1.25 Billion INR | 110.61% |
| 2012 Q3 | 133.84 Million INR | -14.04% |
| 2012 Q4 | 175.2 Million INR | 30.9% |
| 2012 FY | 598.21 Million INR | 5.26% |
| 2012 Q1 | 126.64 Million INR | 0.0% |
| 2012 Q2 | 155.71 Million INR | 22.95% |
| 2011 FY | 568.29 Million INR | 44.45% |
| 2010 FY | 393.42 Million INR | -28.66% |
| 2009 FY | 551.45 Million INR | 0.0% |
| 2008 FY | - INR | -100.0% |
| 2007 FY | 256.31 Million INR | 10.83% |
| 2006 FY | 231.25 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | -18.385% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 83.848% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 24.083% |
| Indoco Remedies Limited | 1.29 Billion INR | -427.385% |
| Achyut Healthcare Limited | 4.43 Million INR | -153498.693% |
| Ajanta Pharma Limited | 19.67 Billion INR | 65.357% |
| Alkem Laboratories Limited | 19.46 Billion INR | 64.974% |
| Alpa Laboratories Limited | 184.49 Million INR | -3594.754% |
| Brooks Laboratories Limited | 14.44 Million INR | -47107.133% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -296.897% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -453.753% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 89.935% |
| Eris Lifesciences Limited | 5.18 Billion INR | -31.553% |
| FDC Limited | 2.98 Billion INR | -128.273% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | -4.834% |
| Gufic Biosciences Limited | 1.32 Billion INR | -412.569% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | -54.205% |
| Ipca Laboratories Limited | 7.98 Billion INR | 14.584% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -1241.529% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 4585.947% |
| Lasa Supergenerics Limited | -458 Million INR | 1588.348% |
| Laurus Labs Limited | 3.94 Billion INR | -72.636% |
| Lupin Limited | 28.04 Billion INR | 75.693% |
| Mankind Pharma Limited | 21.51 Billion INR | 68.321% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -6696.321% |
| Megasoft Limited | -121.1 Million INR | 5728.807% |
| NATCO Pharma Limited | 25.96 Billion INR | 73.744% |
| Piramal Pharma Limited | 4.55 Billion INR | -49.591% |
| RPG Life Sciences Limited | 2.29 Billion INR | -197.374% |
| Sigachi Industries Limited | 1.47 Billion INR | -362.496% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 93.465% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | -47.944% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -2634.878% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -1096.51% |
| Windlas Biotech Limited | 1.29 Billion INR | -424.81% |
| ZIM Laboratories Limited | 253.82 Million INR | -2585.552% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 84.187% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 265.654% |
| Divi's Laboratories Limited | 33.08 Billion INR | 79.393% |
| Hester Biosciences Limited | 364.81 Million INR | -1768.564% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -144.677% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -1389.848% |
| Bal Pharma Limited | 233.9 Million INR | -2814.257% |
| Strides Pharma Science Limited | 5.22 Billion INR | -30.443% |
| Venus Remedies Limited | 534.65 Million INR | -1174.983% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -117.917% |
| Nectar Lifesciences Limited | 923.8 Million INR | -637.894% |
| Shilpa Medicare Limited | 1.36 Billion INR | -398.928% |
| Aarti Drugs Limited | 7.14 Billion INR | 4.644% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -326.898% |
| Suven Life Sciences Limited | -1.22 Billion INR | 656.093% |
| Ind-Swift Limited | 1.22 Billion INR | -456.029% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 52.273% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 276.924% |
| Themis Medicare Limited | 392.58 Million INR | -1636.348% |
| Hikal Limited | 32.11 Million INR | -21129.243% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 73.094% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -988.062% |
| Wockhardt Limited | -670 Million INR | 1117.419% |
| Jubilant Pharmova Limited | 5.18 Billion INR | -31.368% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -75067.444% |
| Neuland Laboratories Limited | 5.31 Billion INR | -28.18% |
| Morepen Laboratories Limited | 4.17 Billion INR | -63.32% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -3176.477% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -24725.952% |